Communiqués Kiora Pharmaceuticals, Inc.

Actions

KPRX

US49721T5074

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
2,550 ^USD	0,00%		-2,67%	+29,44%

19/08	Kiora Pharmaceuticals, Inc. cède les droits de développement et de commercialisation ophtalmiques du KIO-301 en Corée du Sud à Chong Kun Dang Pharmaceutical Corporation	CI
07/08	Kiora Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

19/08	Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation	NE
07/08	Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update	NE
02/07	Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium	NE
18/06	Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model	NE
08/05	Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update	NE
14/04	Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway	NE
07/04	Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors	NE
02/04	Kiora Pharmaceuticals Announces Management Team Changes	NE
25/03	Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials	NE
26/02	Kiora Pharmaceuticals : Overview Feb 2026	PU
19/02	Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference	NE
27/01	Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board	NE
01/12	Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds	NE
07/11	Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases	NE
31/10/25	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders	AQ
15/10/25	Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025	NE
04/09/25	Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference	NE
13/08/25	Kiora Pharmaceuticals : H.C. Wainwright 5th Annual Ophthalmology Virtual Conference	PU
08/08/25	Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases	NE
07/08/25	Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference	NE
22/07/25	Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease	NE
03/06/25	Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia	NE
09/05/25	Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027	NE
05/05/25	Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy	NE
10/04/25	Kiora Pharmaceuticals : 24th Annual Needham Virtual Healthcare Conference	PU